2022 EULAR Recommendations for ANCA-associated Vasculitis EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). https://t.co/kX3dg9DGuw https://t.co/b27CX6Bn0h

LAVLI - A New Autoinflammatory Disorder NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene. https://t.co/VWs0YuF4LD https://t.co/7ydA3bb82j

Docs' Liking for Knee Injection Tied to Industry Payments Physicians accepting payments from drug and device companies administered significantly more hyaluronic acid (HA) injections to Medicare beneficiaries for knee osteoarthritis, researchers found. https://t.co/REtzVjldl2 https://t.co/gfj5cwmVqs

Small trial of MTX vs Apremilast in PsA from India. OL, MD blinded RCT of 31 pts (26 completed). 15 APR vs 16 MTX (had more enthesitis, dactylitis); wk 24 responses favored MTX for major cDAPSA (37% vs 20%; p=0.4), ACR20 (56 v 47%;NS) w/ no diff in AE https://t.co/KIItKgCq4w https://t.co/FG3NV2yLuc

Single center study of 320 Difficult to Rx RA (D2TRA) pts, found 76 EULAR-D2TRA pts (24%). D2TRA more likely to be lower socio-economic, RF+, have ILD, higher DAS28-CRP and were more likely to respond to rituximab and JAK inhibitors https://t.co/aEvP6WDvQu https://t.co/FQJvo81FbM

30 consecutive seropositive (CCP or RF+) early RA pts - 60% had pulmonary abnormalities (PA). PA correlated with presence of neutrophil activation, parameters of inflammation and RF titres. https://t.co/T7CRLzhOMD https://t.co/nYPEw72zOJ

Join RheumNow during the month of April as we discuss Women in Rheumatology, the XX Factor. Sign up to attend our series! https://t.co/m1E4WkK9Cx https://t.co/8RZNgoqzEI

386 pts w/ NPSLE (cerebritis); half (194) were Rx w/ intrathecal MTX+dexamethasone(iMTX); iMTX grp had higher SLEDAI (17 vs 14) & more pulse IV steroids (72% vs 50%). iMTX grp had better survival & NPSLE remission((P=0.042); best w/ ^CSF protein or SZ https://t.co/JsqUrYEwTK https://t.co/np6ntCR9xp

Study of 28,544 gout pts examined fracture risk based on achieving T2T w/ urate-lowering therapy (ULT). The 5 yr risk of hip Fx was 0.5% in those achieving target SU level, but was 0.8% for not achieving SUA target (HR 0.66; 95% CI: 0.46 to 0.93). https://t.co/Yw2zOS0g2v https://t.co/VkGSemlIE4